Novartis receives EU approval for Cosentyx label update

Novartis receives EU approval for Cosentyx label update


Novartis said that the Committee for Medicinal Products for Human Use has approved a label update for Cosentyx , the first interleukin-17A approved to treat psoriasis. FILE PHOTO: The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland, January 25, 2017.



from Biotech News